Frontlight ResearchEarly access
Enrolling by invitationNo phase
Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM)
Key facts
- Who runs it
- Restor3D
- Where
- Charlotte, United StatesSee the site
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 50 people, planned
- Started
- 6 Nov 2024
- Expected to end
- Nov 2031
- Type of study
- Observational
- Treatments tested
- Total Talus Replacement (TTR)
- Record updated
- 8 January 2026
Who can take part
- Age
- 22 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- ≥22 Years of Age
- Scheduled to receive TTR implant for one of the following indications:
- Avascular necrosis of the talus
- Avascular necrosis of the talus in addition to talar collapse, cysts or non-union
- Large, uncontained, unstable, or cystic talar osteochondral defects with risk of collapse or talar osteochondral defects not responsive to traditional treatments
- Nonunion following talar fracture or talar extrusion, unresponsive to more conservative treatments
- Have not had a prior Total Talus Replacement device implanted
- Not planning to receive bilateral Total Talus Replacement devices
- Subject signs a written informed consent form (ICF) prior to the surgical procedure
Who cannot take part
- Surgical procedures other than those listed in the indications for use
- Use of implant greater than 6 months from date of patient's preoperative CT scan
- Blood supply limitations and previous infections that may prevent healing
- Patients with foreign body sensitivity, suspected or documented material allergy or intolerance. Where material sensitivity is suspected, appropriate tests should be conducted, and sensitivity ruled out prior to implantation
- Patients with an active local or systemic infection
- Known history of existing malignancy, or any systemic infection, local infection, or skin compromise at the surgical site
- Physical conditions that would eliminate adequate implant support or prevent healing, including inadequate soft tissue coverage
- Conditions which may limit the patient's ability or willingness to restrict activities or follow directions postoperatively during the healing period
- Degenerative changes in the tibiotalar, subtalar or talonavicular joints
- Gross deformity in sagittal or coronal planes. More than 15 degrees of varus or valgus deformity in the coronal plane, or more than 50% subluxation anteriorly or posteriorly of the talus in the sagittal plane
- Osteonecrosis of the calcaneus, distal tibia or navicular
- Presence of neurological deficit which would prevent patient postoperative compliance
Where in United States
- OrthoCarolina Research Institute, Inc.Charlotte, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This is a Humanitarian Device Exemption (HDE) approved device. The purpose of this study is to evaluate the continued safety and probable benefit of the restor3d Total Talus Replacement device in commercial use.
The group in the trial
- Total Talus Replacement
50 subjects receiving the Total Talus Replacement device
Treatment: Total Talus Replacement (TTR)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM): A Multicenter, Single Arm, Prospective, Post-approval Study for Patients Who Received the restor3d TTR Device to Evaluate Safety and Probable Benefit
- Record updated
- 8 January 2026